Your browser doesn't support javascript.
loading
Missed Cystic Fibrosis Newborn Screening Cases due to Immunoreactive Trypsinogen Levels below Program Cutoffs: A National Survey of Risk Factors.
Kharrazi, Martin; Sacramento, Charlene; Comeau, Anne Marie; Hale, Jaime E; Caggana, Michele; Kay, Denise M; Lee, Rachel; Reilly, Brendan; Thompson, John D; Nasr, Samya Z; Kleyn, Mary; Hoffman, Gary; Baker, Mei W; Clarke, Colleen; Harris, Cheryl L; Dorley, M Christine; Fryman, Hilary; Sutaria, Ankit; Hietala, Amy; Winslow, Holly; Richards, Holly; Therrell, Bradford L.
Afiliação
  • Kharrazi M; California Department of Public Health, Richmond, CA 94804, USA.
  • Sacramento C; Sequoia Foundation, La Jolla, CA 92037, USA.
  • Comeau AM; Sequoia Foundation, La Jolla, CA 92037, USA.
  • Hale JE; New England Newborn Screening Program, UMass Chan Medical School, Worcester, MA 01605, USA.
  • Caggana M; New England Newborn Screening Program, UMass Chan Medical School, Worcester, MA 01605, USA.
  • Kay DM; New York State Newborn Screening Program, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA.
  • Lee R; New York State Newborn Screening Program, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA.
  • Reilly B; Texas Department of State Health Services, Austin, TX 78756, USA.
  • Thompson JD; Texas Department of State Health Services, Austin, TX 78756, USA.
  • Nasr SZ; Washington State Department of Health, Public Health Laboratories, Newborn Screening Program, Shoreline, WA 98155, USA.
  • Kleyn M; Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
  • Hoffman G; Michigan Department of Health and Human Services, Lansing, MI 48913, USA.
  • Baker MW; Wisconsin Newborn Screening Laboratory at Wisconsin State Laboratory of Hygiene, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706, USA.
  • Clarke C; Wisconsin Newborn Screening Laboratory at Wisconsin State Laboratory of Hygiene, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706, USA.
  • Harris CL; Louisiana Office of Public Health, Baton Rouge, LA 70802, USA.
  • Dorley MC; Louisiana Office of Public Health, Baton Rouge, LA 70802, USA.
  • Fryman H; Tennessee Department of Health, Newborn Screening Laboratory and Follow-Up Program, Nashville, TN 37216, USA.
  • Sutaria A; Tennessee Department of Health, Newborn Screening Laboratory and Follow-Up Program, Nashville, TN 37216, USA.
  • Hietala A; Georgia Department of Public Health, Atlanta, GA 30303, USA.
  • Winslow H; Minnesota Department of Health, Public Health Laboratory, Newborn Screening, St. Paul, MN 55164, USA.
  • Richards H; Minnesota Department of Health, Public Health Laboratory, Newborn Screening, St. Paul, MN 55164, USA.
  • Therrell BL; Maine Newborn Screening Program, Augusta, ME 04333, USA.
Int J Neonatal Screen ; 8(4)2022 Oct 27.
Article em En | MEDLINE | ID: mdl-36412584
ABSTRACT
Testing immunoreactive trypsinogen (IRT) is the first step in cystic fibrosis (CF) newborn screening. While high IRT is associated with CF, some cases are missed. This survey aimed to find factors associated with missed CF cases due to IRT levels below program cutoffs. Twenty-nine states responded to a U.S-wide survey and 13 supplied program-related data for low IRT false screen negative cases (CFFN) and CF true screen positive cases (CFTP) for analysis. Rates of missed CF cases and odds ratios were derived for each factor in CFFNs, and two CFFN subgroups, IRT above ("high") and below ("low") the CFFN median (39 ng/mL) compared to CFTPs for this entire sample set. Factors associated with "high" CFFN subgroup were Black race, higher IRT cutoff, fixed IRT cutoff, genotypes without two known CF-causing variants, and meconium ileus. Factors associated with "low" CFFN subgroup were older age at specimen collection, Saturday birth, hotter season of newborn dried blood spot collection, maximum ≥ 3 days laboratories could be closed, preterm birth, and formula feeding newborns. Lowering IRT cutoffs may reduce "high" IRT CFFNs. Addressing hospital and laboratory factors (like training staff in collection of blood spots, using insulated containers during transport and reducing consecutive days screening laboratories are closed) may reduce "low" IRT CFFNs.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Int J Neonatal Screen Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Int J Neonatal Screen Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos